FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 360 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... September 18, 2025 ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... June 12, 2026 The long road to targeting the holy grail of the immune... November 9, 2020 Advancing Patient Care Through Focused Innovation April 16, 2018 Load more HOT NEWS Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers New on NCI’s Websites for March 2021 Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer
